You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Express Scripts
McKesson
Moodys
Mallinckrodt

Last Updated: July 6, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for BIBF1120


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug BIBF1120?

BIBF1120 is an investigational drug.

There have been 18 clinical trials for BIBF1120. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2009.

The most common disease conditions in clinical trials are Carcinoma, Ovarian Neoplasms, and Neoplasms. The leading clinical trial sponsors are Boehringer Ingelheim, European Organisation for Research and Treatment of Cancer - EORTC, and University of Copenhagen.

Recent Clinical Trials for BIBF1120
TitleSponsorPhase
Ph II Nintedanib or Intravenous Ifosfamide Advanced Metastatic STS Failed on Imatinib and SunitinibBoehringer IngelheimPhase 2
Ph II Nintedanib or Intravenous Ifosfamide Advanced Metastatic STS Failed on Imatinib and SunitinibEuropean Organisation for Research and Treatment of Cancer - EORTCPhase 2
Study of Nintedanib Plus Bevacizumab in Advanced Solid TumorsBoehringer IngelheimPhase 1

See all BIBF1120 clinical trials

Clinical Trial Summary for BIBF1120

Top disease conditions for BIBF1120
Top clinical trial sponsors for BIBF1120

See all BIBF1120 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
McKinsey
Express Scripts
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.